Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gillette subpoenas

This article was originally published in The Tan Sheet

Executive Summary

Massachusetts Secretary of the Commonwealth William Galvin issued subpoenas to several Gillette employees May 11 to testify in connection with the State Securities Division's investigation of Procter & Gamble's acquisition of the razor manufacturer. Among those subpoenaed are Gillette CFO Charles Cramb, Board of Directors Vice Chairman Edward Degraan and Human Resources Manager Edward Guillet. Galvin has been investigating the merger since February, shortly after it was announced (1"The Tan Sheet" Feb. 7, 2005, p. 9). Gillette has resisted previous subpoenas issued by Galvin, recently requesting a Massachusetts Suffolk Superior Court quash a request for additional documents pertaining to the merger. The court ruled in favor of Gillette April 28...

You may also be interested in...

State Regulators Understood To Be Eyeing Gillette CEO Package In P&G Deal

The compensation package for Gillette CEO James Kilts outlined under terms of the merger with Procter & Gamble reportedly has drawn the attention of regulatory investigators

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.

Small Firms Get Year Reprieve From Compliance With US FDA’s Supplement Facts Label Changes

FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts